Bryn pharma partners with aptar pharma for nasal epinephrine treatment

Bryn pharma, llc announced that it has entered into an agreement with aptar pharma (aptargroup), for the supply and worldwide exclusive right to use aptar's novel, fda-approved bidose (bds) nasal device for the delivery of epinephrine to treat anaphylaxis. up to 30% of patients who develop anaphylaxis will require a second dose of epinephrine to control symptoms. current practice parameters recommend that physicians prescribe two epinephrine auto-injectors to be carried by their patients at all times. this month, bryn completed dosing in its pivotal clinical trial of its epinephrine nasal spray (bryn-nds1c), using a single, portable, optimized aptar bds device capable of delivering two therapeutic doses of epinephrine, replacing the need to carry two epinephrine auto-injectors.
ATR Ratings Summary
ATR Quant Ranking